FibroGen Ownership
| FGEN Stock | USD 7.71 0.15 1.98% |
Shares in Circulation | First Issued 2013-03-31 | Previous Quarter 100.8 M | Current Value 101 M | Avarage Shares Outstanding 77.9 M | Quarterly Volatility 21.6 M |
FibroGen Stock Ownership Analysis
About 33.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 30.0. FibroGen had not issued any dividends in recent years. The entity had 1:25 split on the 17th of June 2025. FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Fibrogen Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 566 people. To learn more about FibroGen call Enrique Conterno at 415 978 1200 or check out https://www.fibrogen.com.Besides selling stocks to institutional investors, FibroGen also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different FibroGen's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align FibroGen's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
FibroGen Quarterly Liabilities And Stockholders Equity |
|
FibroGen Insider Trades History
Only 1.58% of FibroGen are currently held by insiders. Unlike FibroGen's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against FibroGen's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of FibroGen's insider trades
FibroGen Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as FibroGen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading FibroGen backward and forwards among themselves. FibroGen's institutional investor refers to the entity that pools money to purchase FibroGen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Hightower Advisors, Llc | 2025-03-31 | 404.5 K | State Street Corp | 2025-03-31 | 343.1 K | Ubs Group Ag | 2025-03-31 | 245.6 K | Group One Trading, Lp | 2025-03-31 | 212.1 K | Franklin Street Advisors Inc. | 2025-03-31 | 200 K | Vantage Consulting Group Inc. | 2025-03-31 | 195.7 K | Northern Trust Corp | 2025-03-31 | 177.9 K | Sei Investments Co | 2025-03-31 | 126.8 K | Ci Private Wealth Llc | 2025-03-31 | 102.1 K | Armistice Capital, Llc | 2025-03-31 | 8.5 M | Vanguard Group Inc | 2025-03-31 | 5.9 M |
FibroGen Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific FibroGen insiders, such as employees or executives, is commonly permitted as long as it does not rely on FibroGen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases FibroGen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
FibroGen Outstanding Bonds
FibroGen issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. FibroGen uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most FibroGen bonds can be classified according to their maturity, which is the date when FibroGen has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
FibroGen Corporate Filings
8K | 14th of July 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 2nd of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 6th of June 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 15th of May 2025 Other Reports | ViewVerify |
Pair Trading with FibroGen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if FibroGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in FibroGen will appreciate offsetting losses from the drop in the long position's value.Moving against FibroGen Stock
| 0.64 | KMDA | Kamada | PairCorr |
| 0.54 | CGEN | Compugen | PairCorr |
| 0.51 | KB | KB Financial Group | PairCorr |
| 0.49 | NKTR | Nektar Therapeutics | PairCorr |
| 0.47 | WF | Woori Financial Group Earnings Call Today | PairCorr |
The ability to find closely correlated positions to FibroGen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace FibroGen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back FibroGen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling FibroGen to buy it.
The correlation of FibroGen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as FibroGen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if FibroGen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for FibroGen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.536 | Earnings Share (30.00) | Revenue Per Share | Quarterly Revenue Growth (0.89) | Return On Assets |
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.